

B<sup>5</sup>  
0.005% by weight to approximately 10% by weight, based on the total weight of the pharmaceutical aerosol foam composition.

B<sup>6</sup>  
6. (Amended) A pharmaceutical aerosol foam composition according to Claim 5, wherein the occlusive agent is petrolatum.

7. (Amended) A pharmaceutical aerosol foam composition according to Claim 1, wherein the occlusive agent is present in an amount of approximately 55% by weight or less, based on the total weight of the composition.

Sub C<sub>2</sub>  
18. (Amended) A pharmaceutical aerosol dispenser comprising:  
a pharmaceutical aerosol foam composition including  
an effective amount of a pharmaceutically active ingredient  
an occlusive agent;  
an aqueous solvent;  
an organic cosolvent.  
the pharmaceutically active ingredient being insoluble in both water and the occlusive agent;  
the occlusive agent being present in an amount sufficient to form an occlusive layer on the skin, in use.

Rule 1.126  
Please add new claims 19-32 as follows:

Sub C<sub>2</sub>  
Rule 1.126  
19. A pharmaceutical aerosol foam composition comprising:  
an effective amount of a pharmaceutically active ingredient;  
petrolatum in an amount of approximately 55% by weight or less, based on the total weight of the composition;  
an aqueous solvent; and  
an organic cosolvent,

Sub  
C2  
Rule  
1.12p  
the pharmaceutically active ingredient being insoluble in both water and petrolatum.

21  
20. The pharmaceutical aerosol foam composition according to claim <sup>20</sup>19, wherein the occlusive agent is present in an amount of approximately 10 to 50% by weight, based on the total weight of the composition.

22  
21. The pharmaceutical aerosol foam composition according to claim <sup>20</sup>19, wherein the water insoluble pharmaceutically active ingredient is selected from one or more of the group consisting of an analgesic, anti-inflammatory agent, antifungal, antibacterial, anaesthetic, xanthine, sex hormone, antiviral, antipruritic, antihistamine or corticosteroid.

B  
23  
22. The pharmaceutical aerosol foam composition according to claim <sup>22</sup>21, wherein the pharmaceutically active ingredient is a corticosteroid selected from one or more of the group consisting of betamethasone valerate and clobetasol propionate.

24  
23. The pharmaceutical aerosol foam composition according to claim <sup>20</sup>19, wherein the pharmaceutically active ingredient is present in amounts of from approximately 0.005% by weight to approximately 10% by weight, based on the total weight of the pharmaceutical aerosol foam composition.

25  
24. The pharmaceutical aerosol foam composition according to claim <sup>20</sup>19, further including an effective amount of an emulsifier and/or surfactant.

26  
25. The pharmaceutical aerosol foam composition according to claim <sup>25</sup>24, wherein the emulsifier or surfactant is selected from any one or more of the group consisting of non-ionic, cationic or anionic surfactants, fatty alcohols, fatty acids and fatty acid salts thereof.

27  
26. The pharmaceutical aerosol foam composition according to claim <sup>26</sup>25, wherein the emulsifier includes a mixture of sorbitan monostearate and polysorbate 60.

Rule  
1.126

<sup>28</sup>  
~~27.~~

The pharmaceutical aerosol foam composition according to claim <sup>25</sup>~~24~~, wherein the surfactant component is present in an amount of from approximately 1 to 15% by weight, based on the total weight of the composition.

<sup>29</sup>  
~~28.~~

The pharmaceutical aerosol foam composition according to claim <sup>20</sup>~~19~~, wherein the aqueous solvent is present in an amount of from approximately 25 to 95% by weight, based on the total weight of the composition.

<sup>30</sup>  
~~29.~~

The pharmaceutical aerosol foam composition according to claim <sup>10</sup>~~18~~, wherein the organic cosolvent is present in an amount of from approximately 0.25% by weight to 50% by weight, based on the total weight of the composition.

<sup>31</sup>  
~~30.~~

The pharmaceutical aerosol foam composition according to claim <sup>30</sup>~~29~~, wherein the organic cosolvent is an alkyl benzoate.

<sup>32</sup>  
~~31.~~

The pharmaceutical aerosol foam composition according to claim <sup>20</sup>~~19~~, further including an effective amount of an aerosol propellant.

<sup>33</sup>  
~~32.~~

The pharmaceutical aerosol foam composition according to claim <sup>32</sup>~~31~~, wherein the aerosol propellant is a hydrocarbon and is present in an amount of from approximately 2.5 to 20% by weight, based on the total weight of the composition.

ADD  
C3

#### REMARKS

Applicants' undersigned representative wishes to thank Examiners Dudash and Ostrup for their time and helpful suggestions in the telephone interview held on December 3, 2001, during which the pending claims and prior art were discussed. Claims 1-18 were originally pending. By virtue of this response, claims 1, 3, 4, 6, 7 and 18 have been amended, and new claims 19-32 have been added.